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PREVENTION OF EXPERIMENTAL PERIODONTITIS IN RATS  
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Introduction:  Simvastatin (SIM) is a hypolipidemic drug that has been shown to 
have anti-inflammatory and bone anabolic properties.  The aim of this study was to 
examine the effects of novel locally-applied SIM conjugated with 
methoxypolyethylene glycol to form micelles (SIM/SIM-mPEG) in an experimental 
periodontitis model in rats using micro-computed tomography (µ-CT) and histologic 
evaluation.   
Methods:  Experimental periodontitis was induced using silk ligatures around the 
maxillary right second molar (M2) in 40 Sprague-Dawley rats.  Rats were divided 
into five groups using SIM/SIM-mPEG at 0.5, 1.0, or 1.5 mg SIM doses, mPEG-alone 
or no drug (ligature-alone) injected into the palatal M1-M2 gingiva at baseline and 
1- and 2-weeks post ligature-placement.  Rats were euthanized three weeks after 
baseline and linear measurements were taken using µ-CT from the cementoenamel 
junction (CEJ) to the alveolar bone crest (ABC) between M1-M2.  Using hematoxylin 
and eosin histology, cell counts and area of inflammation were recorded in the 
connective tissue (CT) of the papilla between M1-M2 interproximally.  One-way 
ANOVA and Pearson correlations were calculated. 
Results:  All three doses of the micelle resulted in significantly less bone loss 
compared to the ligature-alone group (p ≤ 0.007).  Significantly greater percentages 
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of lymphocytes were found only in the ligature-alone and mPEG groups compared to 
contralateral controls (p ≤ 0.05).  1.0 and 1.5 mg SIM/SIM-mPEG groups showed 
significantly more uninflamed CT than all other treatment groups (p ≤ 0.05). 
Conclusions:  SIM/SIM-mPEG significantly decreased the amount of bone loss and 
inflamed tissue in experimental periodontitis near the injection site. 
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CHAPTER 1:  INTRODUCTION 
 
 Periodontitis is an inflammatory disease characterized by the loss of the 
supporting tissues of the teeth.  This disease is one of the primary causes of 
permanent tooth loss in man (Albandar et al. 1999).  Based on data collected as part 
of the Center for Disease Control’s 2009-2010 National Health and Nutrition 
Examination Survey (NHANES), periodontitis affects approximately 47.2% of the 
adult population in the United States, equivalent to 64.7 million people (Genco et al. 
2012).   The primary etiological factor in the initiation of periodontitis is the 
bacterial biofilm collecting between the root and sulcular or pocket epithelium.  
However, the periodontopathic bacterial flora is necessary, but not sufficient in and 
of itself for disease activity to occur.  It is the initiation of the individual host’s 
inflammatory response to the bacterial challenge that leads to the destruction of the 
supporting tissues of the teeth (Offenbacher 1996). 
 Most periodontopathic bacteria are gram-negative anaerobic rods and 
spirochetes (Thelaide 1986).  The bacteria invade the host connective tissue (Saglie 
& Elbaz 1983), where a massive accumulation of plasma cells and lymphocytes are 
observed (Allenspach-Petrzilka & Guggenheim 1983).  These cells, among others, 
release a myriad of pro- and anti-inflammatory cytokines.  These cytokines prove to 
be both protective and destructive to the host’s tissues.  When left untreated, this 
process can become primarily pro-inflammatory and lead to increases in exudate 
and probing depths, the apical migration of the junctional epithelium, gingival 
recession, and the loss of alveolar bone and attachment (Schroeder & Lindhe 1975). 
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 Traditional treatment of periodontitis has been aimed at reducing the levels 
and proportions of periodontal pathogens and increasing the proportions of 
beneficial species through both surgical and non-surgical methods (Socransky & 
Haffajee 2002).  Scaling and root planing is the non-surgically based therapy with 
the goal of removing biofilm plaque and calculus from periodontal pockets and 
smoothing the tooth root to remove bacterial toxins, thereby reducing the host-
inflammatory response.  Surgical methods of treatment are aimed at both reducing 
the bacterial load and recontouring or regenerating bone to proper physiologic 
form.   
 Due to the difficulty in adequately reducing bacteria using mechanical means 
alone, antimicrobial agents may be used as adjunctive therapy.  Systemic antibiotics 
have been shown to provide beneficial effects as adjunctive therapy in the treatment 
of chronic and aggressive periodontitis (Sgolastra et al. 2012; Sgolastra et al. 2012).  
These agents are taken orally and affect pathogens via multiple routes, such as 
through accumulation in connective tissue, saliva, and gingival crevicular fluid.  
Local antibiotics are placed into the periodontal pocket and released over time with 
the intention of directly affecting periodontal pathogens and the host response at 
the site(s) of drug delivery only. 
 Host modulation is another method of treatment in periodontal therapy.  
This method aims at affecting the host’s response to the bacterial challenge, 
specifically through agents that inhibit inflammation or affect bone metabolism, 
thereby decreasing the progression of the disease.  These agents include non-
steroidal anti-inflammatory drugs, subantimicrobial dose doxycycline (the only 
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FDA-approved drug for treating periodontitis; Caton et al. 2000), omega-3-fatty 
acids, bisphosphonates, bone morphogenic proteins (BMPs), growth factors, and 
statins.   
 Statins are a class of drugs that have gained research interest in periodontal 
treatment recently.  Simvastatin (SIM) is a hypolipidemic drug that has been found 
to have anti-inflammatory properties (Xu et al. 2012) as well as cause the local up-
regulation of bone growth (Stein et al. 2005).  Despite its findings to be bone 
anabolic, however, its lack of skeletal specificity and low water-solubility via the 
systemic route have prevented its clinical application (Jia et al. 2015).  To address 
these issues, researchers at the University of Nebraska Medical Center have 
designed and prepared a novel macromolecular prodrug of SIM.  The amphiphilic 
macromolecule was prepared by “clicking” an alkyne containing SIM trimer with an 
azido polyethylene glycol monomethylether (mPEG), thus creating the product SIM-
mPEG.  SIM-mPEG can self-assemble into polymeric micelles in water, and free SIM 
can be easily incorporated into the hydrophobic cores of SIM-mPEG micelles to 
produce a SIM/SIM-mPEG micelle.  
A recent study (Jia et al. 2015) found that the SIM/SIM-mPEG micelle could 
boost the differentiation and proliferation of preosteoblasts.  In addition, the 
micelles were used systemically to treat femoral fractures in mice and resulted in 
enhanced callus formation, calcification, and organization.  The study proved that 
the SIM/SIM-mPEG micelle formulation selectively localized to the fracture site and 
was internalized and retained by inflammatory cells present via the extravasation 
through leaky vasculature and inflammatory cell-mediated sequestration (ELVIS) 
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mechanism during the initial inflammatory phase of fracture repair, where it 
exerted a potent and locally sustained bone anabolic effect.  The effects of this 
prodrug in treating periodontitis are unknown, and the hypothesis was formulated 
that SIM/SIM-mPEG would have bone preservation and anti-inflammatory effects in 
experimental periodontitis.  The aim of this study was to examine the effects of 
locally-delivered SIM/SIM-mPEG in an experimental periodontitis model in rats 
using micro-computed tomography (µ-CT) and histologic evaluation.   
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CHAPTER 2:  LITERATURE REVIEW 
 
Alveolar Bone Resorption 
Resorption of the alveolar bone in periodontitis is dependent on 
osteoclastogenesis from hematoprogenitor cells.  An essential molecule in 
osteoclastogenesis is receptor activator of nuclear factor kappa-B ligand (RANKL) 
(McCauley & Nohutcu 2002).  Other mediators playing a role in bone resorption 
include IL-1, IL-6, TNF- α, PGE2, and macrophage colony stimulating factor (M-CSF).  
RANKL is expressed on the cell surface of osteoblasts, stromal cells, or fibroblasts or 
is secreted as a soluble ligand (Belibasakis & Bostanci 2012).  RANKL activates its 
cognate RANK receptor on the surface of pre-osteoclasts and triggers their 
differentiation into mature osteoclasts.  Osteoprotegrin (OPG) is a soluble decoy 
receptor for RANKL.  When OPG is present to bind RANKL, the cell-to-cell signaling 
between osteoblasts and osteoclast precursors is inhibited and osteoclasts are 
unable to differentiate from their precursors (Mogi et al. 2004).  In chronic 
periodontitis the RANKL/OPG ratio demonstrates a 2.2-fold increase compared to 
health, accounting for the alveolar bone resorption seen during disease activity 
(Belibasakis & Bostanci 2012).  
Treatment of Periodontitis 
 Traditional treatment of periodontitis has been aimed at reducing the levels 
and proportions of periodontal pathogens and increasing the proportions of 
beneficial species through both surgical and non-surgical methods (Socransky & 
Haffajee 2002).  Scaling and root planning (SRP) is the nonsurgical-based therapy 
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with the goal of removing plaque and calculus from periodontal pockets and 
smoothing the tooth root to remove bacterial toxins, thereby reducing the host-
inflammatory response.  Cobb (2002) reported decreases in the probing depth (PD) 
and gains in the clinical attachment level (CAL) following therapy.  For 1-3 mm 
pockets treated with SRP a mean 0.03 mm reduction in PD and a mean net loss of 
CAL of 0.34 mm can be expected, for 4-6 mm pockets a mean 1.29 mm PD reduction 
and a mean net gain of CAL of 0.55 mm can be expected, and for pockets 7 mm in 
depth or greater a 2.16 mm PD reduction and a mean net gain in CAL of 1.19 mm can 
be expected.   
When bone morphology or the persistence of deep pockets following non-
surgical therapy continues to promote a state of disease in an individual, the patient 
may be entered into a surgical phase of therapy.  These surgical methods of 
treatment are aimed at both reducing the bacterial load and recontouring or 
regenerating bone to a proper physiologic form.  In a long-term evaluation of 
periodontal therapy, Kaldahl et al. (1996) reported that flap and osseous surgery 
(FO) produced the greatest PD reduction in deep (>5 mm) sites when compared to 
coronal scaling, SRP, and modified Widman surgery (MW).  It was also reported that 
similar CAL gains over time were produced in sites with an initial PD of 7 mm or 
greater treated with SRP, MW, and FO.  The authors concluded that both non-
surgical and surgical periodontal therapy greatly improves the clinical parameters 
of periodontal disease and sustains them long term. 
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Host Modulation 
 In addition to mechanical removal of bacteria with SRP and surgery, host 
modulating agents aim to affect the host response-aspect of the disease process.  
These agents inhibit inflammation or alter bone metabolism, decreasing the 
progression of the disease and include non-steroidal anti-inflammatory drugs 
(NSAIDs), subantimicrobial dose doxycycline (SDD), and statins.   
NSAIDs have been used as an adjunct to periodontal therapy on the basis of 
inhibiting cyclooxygenase and thus prostaglanding synthesis, including PGE2.  A 
clinical trial reported that long-term use of NSAIDs was shown to decrease alveolar 
bone loss in patients with periodontitis (Williams et al. 1989).   One of the 
disadvantages of long-term NSAID use is potential side effects to the liver, kidney, 
and gastrointestinal system.  In a review on the effects of NSAIDs, Salvi & Lang 
(2005) concluded that although some studies present promising results, no data 
from long-term, multicenter prospective clinical trials are available for determining 
whether these therapeutic effects can be retained on a long-term basis. 
Periostat®, or SDD, is available in a 20 mg formulation and has been FDA 
approved in the treatment of chronic periodontitis (Golub 2001).  The regimen 
consists of 20 mg doxycycline taken twice daily for a duration of three to nine 
months.  The clinical efficacy of SDD has been shown to be due, in part, to its ability 
to inhibit collagenolytic matrix metalloproteinases (MMPs) in gingival tissues and 
fluid, specifically MMP-8 and MMP-13 (Golub et al. 1997).  It has been proven that 
long-term treatment with SDD exerts no antibacterial effect on the subgingival 
microflora associated with chronic periodontitis (Walker et al. 2000).  The 
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adjunctive use of SDD with SRP has been shown to be more effective than SRP alone 
in terms of gain in CAL and reduction in PDs in patients with chronic periodontitis 
(Caton et al. 2000).  The major disadvantages to SDD therapy are related to patient 
compliance and the cost associated with prolonged dosage scheduling. 
Statins 
 Statins are a class of drugs that have gained research interest in the 
treatment of periodontal disease.  These drugs are prescribed for the treatment of 
cardiovascular disease, specifically to suppress cholesterol synthesis by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate limiting 
enzyme in the cholesterol metabolism pathway.  In addition to the cholesterol-
lowering effect, statins have a series of pleiotropic effects, including bone anabolic 
and anti-inflammatory properties (Mundy 2001).  The bone anabolic properties 
associated with statins can be summarized into three major mechanisms:  the 
promotion of osteogenesis, the suppression of osteoblast apoptosis, and the 
inhibition of osteoclastogenesis (Zhang et al. 2014).  Statins’ promotion of 
osteognesis relates to their ability to stimulate the expression of BMP-2, their anti-
osteoblast apoptosis effects relate to their role in altering the transforming growth 
factor-beta (TGF-β)/mothers against decapentaplegic homolog 3 (Smad3) signaling 
pathway, and their anti-osteoclastic effect seems to be due to their effect on the 
OPG/RANKL/RANK signaling pathway.  Locally-applied BMP-2 has been used to 
stimulate craniofacial bone formation (Triplett et al. 2009), but it is not approved 
specifically for periodontitis and costs/morbidity may be prohibitive.  Although 
these effects would be beneficial in the treatment of bone-catabolic diseases such as 
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osteoporosis or periodontitis, their lack of skeletal specificity, low water-solubility, 
and first pass effect that takes place in the liver has prevented their clinical 
application.  Systematic reviews of human studies of orally administered statins and 
bone effects over the past 10 years generally have come to the conclusion that their 
impact is modest (Zhang et al. 2014). 
Simvastatin 
 Simvastatin (SIM) is a statin formulation that has been studied in the 
treatment of periodontitis.  In a study (Vaziri et al. 2007) where SIM was injected 
subperiosteally following ligature-induced bone-resorption around mandibular 
teeth in ovariectomized rats, simvastatin groups developed significantly less 
periodontal breakdown.  Another study (Seto et al. 2008) using ligatures around 
maxillary molars of rats to induce periodontitis found that local SIM topically 
injected into periodontal defects recovered the ligature-induced alveolar bone 
resorption, showing a 46% reversal of bone height loss.   Another study (Price et al. 
2013) used a SIM/alendronate-β-cyclodextrin complex that was injected prior to the 
induction of experimental periodontitis in rats.  Results showed that this SIM 
complex has the potential to prevent episodes of periodontitis bone loss.  The 
authors also noted that both the increase in osteoclasts and subsulcular 
inflammation seen in the experimental periodontitis model were reduced when 
preceded by treatment with the SIM complex.  However, Powell (2011) found that 
neither prophylactic nor therapeutic local injections of SIM provided beneficial 
effects on alveolar bone or CT attachment levels in the treatment of 
lipopolysaccharide (LPS) injection-induced experimental periodontitis in rats.   
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 A limited number of human clinical studies have also reported on the effect 
of simvastatin in the treatment of periodontitis.  In a study of 60 patients receiving 
SRP plus either a locally delivered placebo or SIM, there was a greater decrease in 
gingival inflammation and significantly more intrabony defect fill at sites treated 
with SRP plus SIM (Pradeep & Thorat 2010).  Another similarly designed study by 
the same group examining SIM’s effect in treating molar Class II furcation defects in 
72 patients resulted in a similar reduction in gingival inflammation and greater 
mean percentage of bone fill in SIM-treated subjects (Pradeep et al. 2012).  The 
authors concluded that locally delivered SIM provides a comfortable and flexible 
method to improve clinical parameters and also enhance bone formation.  Also, 38 
subjects with type 2 diabetes similarly treated with SIM resulted in the same 
inflammation reduction with significant intrabony defect fill at sites treated with 
SRP plus locally delivered SIM compared to SRP alone (Pradeep et al. 2013).  While 
the human trials above are supportive of the use of statin treatment of periodontitis 
and other craniofacial defects, Zhang et al. (2014) states that future confirmation of 
these results by other investigators is crucial.   
SIM/SIM-mPEG 
 To address statins’ lack of skeletal specificity, low water solubility, and first 
pass effects, investigators at the University of Nebraska Medical Center College of 
Pharmacy have developed a novel macromolecular prodrug of SIM designed and 
prepared by chemically conjugating multiple SIM molecules to the chain terminus of 
methoxy polyethylene glycol (mPEG).  This amphiphilic macromolecular prodrug 
(SIM-mPEG) can be further formulated into micelles loaded with free SIM (SIM/SIM-
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mPEG).  When tested to examine the effects of intravenously administered SIM/SIM-
mPEG on femoral fractures in mice, the results showed that the SIM/SIM-mPEG-
treated mice exhibited a potent and locally sustained bone anabolic effect with 
consolidated calcified callus formation, while control and conventional SIM-treated 
mice were found with foci of immature callus with relatively low density (Jia et al. 
2015).  The micro-computed tomography (µ-CT) analysis suggested that the 
SIM/SIM-mPEG formulation enhanced callus formation, calcification, and 
organization. 
Experimental Periodontitis Models 
It has been demonstrated that the structure and organization of the 
periodontal tissues of the molars in rats are similar to those of humans (Listgarten 
1975).  However, rats are not susceptible to the development of natural 
periodontitis and periodontal destruction must be induced experimentally 
(Pellegrini et al. 2009).  The most commonly used methods to induce periodontitis 
include the placement of ligatures into the sulci around teeth or the injection of LPS 
directly into the periodontium.  Currently there is no universally accepted, proven 
method that acts as a standard in the creation of an experimental periodontitis 
defect in rats. 
The direct injection of LPS into the gingiva has been reported to induce 
biochemical changes that parallel natural adult periodontitis.  Ramamurthy et al. 
(2002) reported that 10 µL of Escherichia coli LPS (1 mg/mL) given through three 
injections (every other day for five days) resulted in a loss of alveolar bone in a 
short time frame.  Dumitrescu et al. (2004) reported that the tightly bound tissue of 
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the gingiva in rats would not expand to accommodate an injection of 10 μg LPS in a 
volume of 10 μL saline and much of the injected volume was lost along the needle 
tract.  To adjust for this, the authors reported that 10 μg LPS in a volume of 1 μL 
saline resulted in significant gingival and periodontal inflammation with 
inflammatory infiltrate, apical migration of the JE, interdental bone loss, and 
activation of osteoclasts at the site of injection.  Price et al. (2013) demonstrated 
that 10 μL of E coli LPS injected into the palatal/interproximal gingiva of rat molars 
resulted in a reduction of bone volume, density, and thickness.  These LPS injections 
also gave histologic evidence of increased osteoclasts and subsulcular inflammation.   
The ligature model of experimental periodontitis is considered to be more 
representative of periodontitis in humans mainly because of the participation of live 
microorganisms with diverse virulent factors other than LPS.  This greater diversity 
of antigens may result in a more complex host response, which may have an effect 
on the cytokine and inflammatory mediator network (de Aquino et al. 2009).  
However, the physical pressure of the ligature may induce mechanical stripping of 
periodontal attachment, not consistent with naturally occurring periodontitis.   It 
has been reported (Spolidorio et al. 2014) that the use of a ligature around the 
maxillary 2nd molar results in a significant increase in IL-1β, TNF-α, and IL-6 levels 
at days 8 and 15 in the gingival tissues surrounding ligated teeth compared to non-
ligated teeth.    Another study (Furlaneto et al. 2014) where ligatures were placed 
around maxillary 2nd molars reported greater alveolar bone loss in experimental 
periodontitis groups at buccal, palatal, furcation, and interproximal sites compared 
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to control groups with attachment loss and a moderate-to-severe inflammatory 
infiltrate. 
Micro-computed Tomography 
 µ-CT is a three-dimensional (3-D) reconstruction technique that can image 
specimens on the micron level and allow for computer-aided reorientation following 
image scanning (Park et al. 2007).  Specifically, this method allows for the 
production of 3-D images of mineralized tissue (bone, teeth) to analyze the 
architecture and slight deviations in alveolar bone loss (Mengel et al. 2005).  Due to 
the ability to maintain the tissues during and after µ-CT, histology can be performed 
later.  µ-CT has been used to analyze alveolar bone loss in ligature-induced 
periodontitis in rats (Furlaneto et al. 2014, Spolidorio et al. 2014), and results 
obtained from µ-CT were found to be virtually identical to those obtained from 
histology in the analysis of periapical bone loss in mice (Balto et al. 2000). 
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CHAPTER 3:  MATERIALS AND METHODS 
 
Pilot Study 
 The hypothesis was that the ligatures would attract bacteria and allow build-
up in the gingival sulcus.  In addition, ligatures would also help create inflammation 
and bone loss and allow for an increased volume of LPS (and/or experimental drug 
in the main study) to be injected into the periodontium to further produce 
inflammation. The aim of the pilot study was to determine the most effective 
method to induce experimental periodontitis, specifically testing whether ligatures 
alone, LPS injections alone, or a combination of the two methods produce the most 
periodontitis-like bone loss in rats.  The most destructive model, measured by 
alveolar bone loss, was desired for use in the core study.   
Three groups of five mature Sprague-Dawley female rats were used for the 
pilot study.  All animals were treated and housed in the University of Nebraska 
Medical Center (UNMC) College of Dentistry Animal Facility under the auspices of 
the UNMC Institutional Animal Care and Use Committee (IACUC #13-006-03-FC).  
These rats were allowed to acclimate one week prior to the first procedure.  Rats 
were divided into groups as shown in Table 1.  Groups 1 and 3 had 4-0 silk ligatures 
tied around the maxillary right 1st molars at the initiation of the study.  E coli LPS 
injections (10 µg in a volume of 1 µL saline) were delivered to the distopalatal 
aspect of the maxillary right first molar (M1) every other day for five days during 
the first week for Group 2, and during the second week for Group 3 (following 
ligature placement).  The contralateral maxillary first molars served as untreated 
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controls.  All animals were euthanized via CO2 asphyxiation on the first day of the 
second week following the final treatment of experimental periodontitis 
induction—week three for groups 1 and 2, and week four for Group 3.  The palates 
with all three bilateral maxillary molars and their associated periodontium were 
removed via block resection and stored in 10% formalin.  Specimens were scanned 
and analyzed with µ-CT using methods described in the core study.  The sole 
purpose of using µ-CT in the pilot was to become familiar with the methods for the 
core study.  Sections were then prepared for hematoxylin and eosin (H&E) histology 
using methods described in the core study.  Using both µ-CT and histology, the 
amount of bone loss was determined using a linear measurement from the CEJ to 
the alveolar bone crest (ABC) at the distopalatal aspect of M1, with the histologic 
measurements used as the primary outcome.  In addition, inflammation was 
categorized using a scoring system described by Coimbra et al. (2011):  0, no 
inflammatory cells; 1, slight inflammation (few inflammatory cells); 2, moderate 
inflammation (remarkable inflammatory cells scattered throughout the connective 
tissue above the bone crest); 3, severe inflammation (predominance of 
inflammatory cells).  To assess differences of measurements among groups one-way 
ANOVA was completed. 
Core Study 
The core study consisted of 40 mature retired-breeder female Sprague 
Dawley rats (Harlan Teklad, Madison, WI).  All animals were treated and housed in 
the University of Nebraska Medical Center (UNMC) College of Dentistry Animal 
Facility under the auspices of the UNMC Institutional Animal Care and Use 
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Committee (IACUC #13-006-03-FC).  These rats were allowed to acclimate one week 
prior to the first procedure. 
Synthesis of SIM/SIM-mPEG 
 The SIM/SIM-mPEG micelles were suspended in a PBS solution as a releasing 
medium.  Synthesis of the micelle has been described previously (Jia et al. 2015, 
Figure 1).  Briefly, the dendritic amphiphilic SIM prodrug was designed by 
conjugating a cluster of three SIMs covalently to the chain terminus of mPEG.  In 
designing the hydrophobic SIM trimer block, an ester bond was selected as the 
chemical linkage as it can not only hold the three SIMs together, but also can be 
hydrolyzed in vivo by esterases to release the conjugated SIM.  Of the 3 SIMs 
conjugated to mPEG, two are in the prodrug form with an intact lactone ring and the 
other SIM is in the form of simvastatin acid.  When exposed to in vivo environmental 
factors (esterases, water, acidity, elevated temperature, etc.), the lactone ring will 
open to produce the active form of the drug simvastatin acid.  Therefore, all of the 
drug released will be in the bioactive form. Click chemistry was then used to 
conjugate the SIM trimer to the mPEG terminus to form the amphiphilic 
macromolecule, which self assembles into micelles.  Because of the structural 
similarity between SIM and the SIM trimer, free SIM can be incorporated into the 
hydrophobic core to form SIM/SIM-mPEG micelles, which permits additional drug-
loading capacity.  
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Anesthesia 
All animals were weighed following anesthesia induction and prior to all 
procedures to monitor weight gain/loss.  Each animal was initially placed into an 
induction chamber attached to an isofluorane anesthetic vaporizer and anesthesia 
was induced to effect with 1-4% isofluorane/100% O2 (1-3 L/min), followed by 
application of a nose cone with 0.5-2% isofluorane/100% O2 (0.5-1 L/min) to 
maintain anesthesia during the experimental procedures.  Following injections and 
anesthesia, rats were monitored until awake and normal movement was noted 
(hourly for the entire day). 
Experimental Periodontitis and Experimental Groups 
Experimental periodontitis was induced using 4-0 silk ligatures around the 
maxillary right second molar in all 40 Sprague-Dawley rats (Figure 2).  Ligatures 
were selected because a pilot study determined experimental periodontitis to be 
induced most effectively using ligatures compared to Escherichia coli 
lipopolysaccharide (LPS) injections alone as well as E coli LPS injections in 
combinations with ligatures.  Rats were divided into five groups of eight rats each as 
outlined in Table 2.  The local injections of the drug or carrier were delivered to the 
palatal gingiva between the maxillary right first (M1) and second molars (M2) using 
an insulin syringe with a 30-gauge needle (Becton Dickinson, Franklin Lakes, NJ) 
(Figure 3).  All ligatures were removed after one week and injections were delivered 
at baseline following ligature placement (week one) and on the first day of weeks 
two and three.  The contralateral maxillary molars received no treatment and 
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served as untreated controls of the preceding treatment group (Groups 2, 4, 6, 8, & 
10).   
Euthanasia 
All animals were euthanized on the first day of week four by CO2 
asphyxiation.  Animals were weighed following euthanasia and the maxilla was then 
separated from the rest of the skull.  The entire palate was placed in 10% formalin 
for storage prior to scanning with the µ-CT. 
Micro-computed Tomography Measurements 
 The palates were scanned using a high-resolution µ-CT system (Skyscan 
1172;Skyscan, Kontich, Belgium).  Each maxilla was scanned and reconstructed into 
a 3D-structure with a pixel size of 8.71 µm.  The X-ray tube voltage was 70 kV and 
the current was 141 µA, with a 0.5 mm thick aluminum filter.  Exposure time was 
580 ms.  The X-ray projections were obtained at 0.7° intervals with a scanning 
angular rotation of 180° and eight frames were averaged for each rotation.  3D 
reconstructions were performed using NRecon software.  Using Data Viewer (v. 
1.5.0, Bruker), the generated 3D models were rotated into a standard position 
according to the following criteria: 1) in the transaxial plane, the maxillary first 
molar had its axis vertically positioned; 2) in the coronal plane, the roots in cross 
section were positioned vertically; 3) in the sagittal plane, all teeth were positioned 
horizontally with the first molar (M1) positioned to the right (Figure 4).  The sagittal 
dataset was analyzed using software (CT-Analyzer, v. 1.13, Bruker) and the distance 
from the CEJ to the alveolar bone crest (CEJ-ABC) was measured at the distal of M1 
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(M1D, primary outcome site that was not mechanically affected by the ligature or 
injections) and mesial and distal aspects of the second molar (M2M & M2D, 
respectively).  The image (Figure 5) where the roots were in an even plane with 
their respective canal spaces widest mesio-distally was used for measurement and 
all measurements were performed by one examiner (AB) who was masked to the 
experimental groups and treatments rendered.  Ten percent of the sites were then 
re-coded and re-measured at random to evaluate intra-examiner reliability. 
Histology 
 All specimens were decalcified in 5% formic acid solution for approximately 
one month.  Following decalcification, the specimens were processed and embedded 
in paraffin in a conventional manner.  Serial sections 5-µm thick were obtained in a 
mesio-distal direction with the roots aligned in one plane.  The sections were 
stained with hematoxylin and eosin (H&E) for analysis by light microscopy.  
 In order to characterize the connective tissue (CT) and inflammatory 
infiltrate, cell counts were completed at the area of interest, specifically in the CT of 
the papilla between M1-M2 interproximally.  This was completed using direct grid-
point counting of cells in 100 point intersects under 400× magnification with a light 
microscope (Nikon Optiphot, Tokyo, Japan).  Intersections were identified as 
containing one of the following:  uninflamed collagen, fibroblasts, 
polymorphonuclear leukocytes (PMNs), lymphocytes, plasma cells, macrophages, 
endothelial cells/blood vessel lumens, or spaces/other. 
 Images of the histologic sections were captured at a magnification of 40× 
with a digital camera (ProgRes C3, JENOPTIK).  The images were saved on a 
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computer and then analyzed using appropriate software (ProgRes CapturePro v. 
2.8.8, JENOPTIK).  The images were calibrated by linear measurements and the area 
of inflammatory infiltrate and the total area of CT (collagen and fibroblasts) above 
the area of alveolar crest interproximally between M1 and M2 were measured, 
which allowed for a calculation of the ratio of the area of inflammatory infiltrate to 
the total area of CT above the alveolar bone crest (% INF).  In addition, the length of 
CT attachment to interproximal roots was measured.  All measurements and cell 
counts were performed by one examiner (AB) who was masked to the experimental 
groups and treatments rendered and 10% of the specimens were confirmed by an 
oral pathologist (NN). 
Statistical Analysis 
 Eight rats per group were used in this study based on histological detection 
of bone gain with administration of 0.5 mg SIM injections with 5-8 rats per group 
(Lee et al. 2008).  Each rat was used as a different experimental subject and as the 
unit of measurement for primary outcomes.  The data obtained in the analyses were 
grouped and presented as means ± standard errors of the mean (SEM).  To assess 
differences of measurements among groups for all measurements, one-way analysis 
of variance (ANOVA) was completed.  Pearson correlations were calculated for 
associations between the % INF and amount of bone loss.  The single measures 
intra-class correlation coefficient (ICC) was calculated to evaluate the intra-
examiner reliability between the µ-CT measurements collected at two different 
measurement times.  The significance level was set at p ≤ 0.05 in all tests. 
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CHAPTER 4:  RESULTS 
 
Pilot Study 
 The mean distance from the CEJ to the alveolar crest at the distal of M1 
(Figure 6) was 1.174 mm for Group 1 (ligature-alone), 1.105 mm for Group 2 
(ligature + LPS), and 0.680 mm for Group 3 (LPS-only).  Both of the measurements 
in Groups 1 and 2 were significantly greater than their contralateral controls (p = 
0.03 & 0.006, respectively).  The measurement for Group 3 was not significantly 
different than its contralateral control.  Both Groups 1 and 2 caused significantly 
greater bone loss compared to Group 3 (p = 0.011 & 0.015, respectively).  There was 
no difference in bone loss between Groups 1 and 2.  Measurements taken using µ-CT 
confirmed the histologic measurements (Figure 7). 
 The scores for subepithelial inflammation for ligature-alone, ligature plus 
LPS, and LPS-alone groups were 1.75, 2.2, and 1.6, respectively, with no significant 
differences among groups.  The ligature-alone and ligature plus LPS groups both had 
significantly greater inflammatory scores than their contralateral controls (p = 
0.008 & 0.026, respectively), while the difference in the LPS-alone group was not 
statistically significant (Figure 8). 
 LPS-alone in the concentration used (10 µg/µL) was not an effective method 
to induce experimental periodontitis in rats.  Both ligatures alone and ligatures plus 
LPS injections effectively induced experimental periodontitis as determined by 
interproximal bone loss; however, there was no additional benefit with the addition 
of LPS in the ligature model.  It can be concluded from the pilot study that 
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experimental periodontitis can be induced effectively with ligatures alone.  The 
hypothesis that ligatures would help create inflammation and bone loss and allow 
for an increased volume of LPS (and/or experimental drug in the main study) to be 
injected into the periodontium may be true, but the addition of LPS did not create a 
more destructive periodontal lesion. 
Core Study 
 All animals’ weights averaged greater than 300 grams at the conclusion of 
the study.  The mean changes in weight from the start to the end of the study for all 
groups were within 10 grams of the starting weights (Figure 9), and these changes 
were not significantly different among groups (p = 0.1315). 
Micro-computed Tomography 
 At the primary outcome site (M1D), Group 9 (1.5 mg SIM/SIM-mPEG) 
showed the least amount of bone loss compared to all other groups (Figure 10).  The 
mean distance from the CEJ-ABC for Group 9 was 0.68 mm ± 0.05, for Group 7 (1.0 
mg SIM/SIM-mPEG) was 0.75 mm ± 0.06, for Group 5 (0.5 mg SIM/SIM-mPEG ) was 
0.77 mm ± 0.06, for Group 3 (mPEG) was 0.85 mm ± 0.06, and for Group 1 (ligature-
alone) was 1.00 mm ± 0.06.  Each group showed significantly greater bone loss than 
their contralateral untreated controls, and all three increasing doses of SIM/SIM-
mPEG showed significantly less bone loss than ligature-alone (p = 0.007, 0.005, & 
0.0002, respectively).  In addition, 1.5 mg SIM/SIM-mPEG showed significantly less 
bone loss than mPEG (p = 0.04).  Bone loss at M2M and M2D was not significantly 
different among treatment groups (Figures 11 & 12, respectively).  Finally, the 
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single measures ICC was 0.985 (95% confidence interval: 0.961 to 0.994), indicating 
a high intra-examiner reproducibility of measurements taken using the µ-CT system 
(Table 3). 
Histology 
 The length of CT attachment was not significantly different among treatment 
groups (Figure 13).  Each treatment group had a significantly greater length of CT 
attachment compared to their contralateral controls, except for 1.5 mg SIM/SIM-
mPEG.   
Each treatment group showed significantly greater areas of inflammation 
between M1 and M2 compared to their respective contralateral untreated control 
(Figure 14).  Also, 1.0 mg SIM/SIM-mPEG showed a significantly greater area of 
inflammatory infiltrate compared to ligature-alone and mPEG groups (p = 0.002 & 
0.03, respectively).  No significant difference was observed among groups for % INF 
(p = 0.23).   Also, no correlation was found between the % INF and bone loss at both 
M1D and M2M (Table 4).  
 Significantly greater percentages of lymphocytes (Figure 15) were found in 
the ligature-alone and mPEG groups compared to their contralateral controls (p = 
0.05 & 0.003, respectively).  Differences between specific dosages of SIM/SIM-mPEG 
compared to their contralateral untreated controls did not reach statistical 
significance.  There were no significant differences in lymphocyte percentages for 
SIM/SIM-mPEG groups compared to ligature-alone and mPEG groups. 
 The percentage of PMNs (Figure 16) was significantly decreased in the 1.5 
mg SIM/SIM-mPEG group compared to 0.5 mg SIM/SIM-mPEG and mPEG groups (p 
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= 0.02 & 0.03, respectively).  No significant differences in PMN counts were 
observed between treatment groups and their contralateral controls. 
 A greater percentage of uninflamed CT (Figure 17) was observed for 1.0 mg 
SIM/SIM-mPEG compared to ligature-alone, mPEG, and 0.5 mg SIM/SIM-mPEG 
groups (p = 0.04, 0.0006, & 0.006, respectively), as well as 1.5 mg SIM/SIM-mPEG 
compared to mPEG and 0.5 mg SIM/SIM-mPEG (p = 0.001 & 0.009, respectively), 
and approached statistical significance when 1.5 mg SIM/SIM-mPEG was compared 
to ligature-alone (p = 0.07).  Differences between dosages of SIM/SIM-mPEG and 
their contralateral untreated controls did not reach statistical significance, while 
ligature-alone and mPEG groups revealed significantly less uninflamed CT 
compared to their contralateral controls. 
 There were no significant differences observed between cell counts of 
fibroblasts, macrophages, plasma cells, endothelial cells/blood vessel lumens, or 
spaces/other. 
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CHAPTER 5:  DISCUSSION 
 
Pilot Study 
 The results from the pilot study confirmed that the use of a ligature alone is 
an effective method to create an experimental periodontitis model in a rat.  This 
method produced a significant amount of bone loss compared to its contralateral 
untreated control (p = 0.03), as well as a significant difference compared to LPS 
alone (p = 0.011).  No significant difference was found between the ligature alone 
and ligature plus LPS groups.  In addition, the ligature-alone method produced a 
significantly greater amount of inflammation when compared to its contralateral 
untreated control.  Spolidorio et al. (2014) found after placing cotton ligatures 
around the maxillary 2nd molars of rats that a clear evolution of the inflammatory 
process was evident.  The authors also noted significant increases in IL-1β, TNF-α, 
and IL-6 following ligature-induced periodontitis and stated this method 
demonstrates a satisfactory outcome of the experimental periodontitis model.  
Furlaneto et al. (2014) also used a ligature to induce experimental periodontitis 
around the maxillary 2nd molar of rats.  These authors observed a greater amount of 
alveolar bone and attachment loss and moderate-to-severe inflammatory infiltrate 
in experimental periodontitis rats compared to control (no treatment) at all sites 
analyzed (buccal, palatal, furcation, and interproximal).  The authors further stated 
that this model allows for the successful induction of experimental periodontitis, 
which was in accordance with the current pilot study.   
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 The LPS injections provided no additional benefit when used in addition to a 
ligature and were unable to produce a significant amount of bone loss when used 
alone in a series of 3 injections over one week.  In addition, LPS injections-alone in a 
1 µL volume did not produce a greater amount of inflammation compared to the 
untreated control.  These results contradict those of Price et al. (2013), who 
reported that 10 µL of E coli LPS injected into the palatal/interproximal gingiva of 
rat molars resulted in an increase in subsculcular inflammation.  Dumitrescu et al. 
(2004) also reported that 10 µg of LPS in a volume of 1 µL saline injected three 
times over one week resulted in significant gingival and periodontal inflammation 
with inflammatory infiltrate, apical migration of the junctional epithelium, 
interdental bone loss, and activation of osteoclasts at the site of injection.  
Ramamurthy et al. (2002) reported that 10 µL of E coli LPS (1 mg/mL) given 
through three injections over one week resulted in a loss of alveolar bone in a short 
time frame.  This pilot study is in contrast to these reports as well.  The reason the 
pilot study conflicted with the aforementioned reports could be explained by the 
difficulty in injecting the entire volume of LPS into the palatal tissue.  For example, it 
was possible that a portion of the 1 µL volume remained in the needle lumen 
through capillary action, the bevel on the needle could have been too large to allow 
for the entire volume to enter the palatal tissue, and the taut nature of the palate 
could have resisted the injection pressure placed on the syringe, preventing the 
volume from entering the connective tissue space. 
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Core Study 
 The results of the core study showed that SIM/SIM-mPEG significantly 
decreased the amount of bone loss and inflamed tissue near the injection site.  At the 
primary outcome site, 1.5 mg SIM/SIM-mPEG resulted in the least amount of bone 
loss compared to all other treatment groups.  However, differences among 
individual doses of SIM/SIM-mPEG were not statistically significant.  All three doses 
of the experimental micelle resulted in significantly less bone loss compared to the 
ligature-alone group, and 1.5 mg SIM/SIM-mPEG was the only dosage that resulted 
in significantly less bone loss than the mPEG treatment group.  No differences 
among groups were seen at M2M and M2D, likely due to the trauma induced at the 
injection site (M2M) and inability of the drug to exert its effects in sites not in the 
close vicinity of drug delivery (M2D).   
In a study (Vaziri et al. 2007) using ovariectomized (OVX) rats with ligature-
induced periodontitis around mandibular molars where SIM was administered 
subperiosteally into the buccal mucosa, it was concluded that SIM showed 
protective features against the impact of periodontitis on the attachment apparatus 
and alveolar bone.  Similarly, a study by Xu et al. (2014) found that local SIM 
administration in OVX rats with ligature-induced experimental periodontitis around 
maxillary M1 and M2 resulted in increased alveolar crest height and prevented local 
alveolar bone loss.  Another study (Seto et al. 2008) using local SIM topically 
injected into periodontal defects created with ligatures around maxillary molars of 
rats showed that SIM recovered the ligature-induced alveolar bone resorption, 
showing a 46% reversal of bone height loss.   Price et al. (2013) used a 
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SIM/alendronate-β-cyclodextrin complex that was injected prior to the induction of 
experimental periodontitis in rats and showed that this SIM complex has the 
potential to prevent episodes of periodontitis bone loss.   The results of this study 
confirm the bone-preservation and potentially bone-regenerative effects of SIM that 
was observed in these reports.  Because one SIM/SIM-mPEG injection was placed at 
the time of ligature placement and two subsequent injections were placed following 
experimental periodontitis induction, a combination of bone-preservation and 
bone-regenerative effects may have been observed.  Future studies with all local 
applications applied following ligature removal are needed to confirm the 
regenerative capabilities of SIM/SIM-mPEG. 
The length of connective tissue attachment was not significantly different 
among treatment groups.  Each group, regardless of experimental protocol 
(injections or ligature-alone), showed significantly greater areas of inflammation 
above the alveolar bone crest compared to their respective contralateral controls.  
In addition, 1.0 mg SIM/SIM-mPEG showed a significantly greater area of 
inflammatory infiltrate compared to the ligature-alone and mPEG groups.  The % 
INF also revealed no significant differences among groups, nor was there a 
correlation found between the % INF and bone loss near the injection site (M1D & 
M2M).  The rationale as to why bone changes were observed at the primary 
outcome site without differences in % INF through SIM/SIM-mPEG injections is 
unknown, but could possibly be explained due to the effects the drug has on 
processes directly associated with bone loss, such as decreasing osteoclast 
differentiation by increasing the OPG/RANKL ratio, increasing osteoblast 
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differentiation by up-regulating BMP-2, and decreasing osteoblast apoptosis by 
increasing TGF-β receptors.  Thus, the area of inflammation induced by 
experimental periodontitis may have been without consequence when treating with 
SIM/SIM-mPEG.  This conclusion is supported by the results of Dalcico et al. (2013), 
who reported that orally administered SIM in rats with experimental periodontitis 
induced with nylon ligatures around maxillary 2nd molars resulted in a significant 
inhibition of bone loss as well as a reduced expression of RANKL and an increased 
expression of BMP-2 and OPG levels.   
The percentage of PMNs was significantly decreased in the 1.5 mg SIM/SIM-
mPEG group compared to 0.5 mg SIM/SIM-mPEG and mPEG groups.  This dose-
response trend confirms the findings of Dalcico et al. (2013), in which the authors 
reported a dose-dependent reduction in myeloperoxidase (MPO) activity (an 
indicator of the extent of neutrophil accumulation) in the gingival tissue of SIM-
treated- compared to saline-treated-rats.  
Lymphocytes were the predominant cell type found in the inflammatory 
infiltrate of the connective tissue at day 28 (termination of the study), 
demonstrating the chronic nature of the experimental periodontitis lesion at this 
time-point.  This finding is in accordance with the findings of Menezes et al. (2005) 
and Lima et al. (2000), which demonstrated an intense inflammatory cell infiltrate 
of mononuclear cells by day 11 with ligature-induced periodontitis around the 2nd 
maxillary molar in rats.  The ligature-alone- and mPEG-treated rats in the current 
study were found to have significantly greater percentages of lymphocytes 
compared to their contralateral untreated controls, indicating both the effectiveness 
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of the use of a ligature in the initiation of experimental periodontitis and the pro-
inflammatory property of the mPEG carrier.  The difference in lymphocyte count for 
each dose of SIM/SIM-mPEG compared to their respective contralateral untreated 
controls was not statistically significant, suggesting a trend toward health with 
SIM/SIM-mPEG use.  However, there was no significant difference in this cell type 
for these doses compared to the ligature-alone and mPEG groups; thus, no definitive 
correlation regarding a decrease in lymphocytic infiltrate with the use of SIM/SIM-
mPEG could be proven. 
SIM/SIM-mPEG resulted in a significantly greater percentage of uninflamed 
CT in the 1.0 mg dose compared to ligature-alone, mPEG, and the 0.5 mg dose.  
Increased uninflamed CT was also noted in the 1.5 mg dose compared to mPEG and 
the 0.5 mg dose.  The 1.5 mg dose of SIM/SIM-mPEG, when compared to ligature-
alone, approached a statistically significant increase (p = 0.07).  Thus, a dose-
response trend was observed regarding SIM/SIM-mPEG and uninflamed CT fibers.  
Results also indicated that the inflammatory infiltrate in the connective tissue of the 
papilla between M1-M2 interproximally was localized to the lamina propria directly 
underlying the sulcular and junctional epithelium, and did not advance towards the 
alveolar bone crest.  This also could contribute to the bone-preservation effect seen 
with SIM/SIM-mPEG at the primary outcome site.  Furthermore, the mPEG group 
revealed the least amount of uninflamed CT, and as mentioned above, had 
significantly greater counts of PMN infiltrate compared to SIM/SIM-mPEG doses.  
Collectively, it can be concluded that the mPEG carrier alone increased inflammation 
histologically in this study. 
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A limited number of human studies have reported on the effects of SIM in the 
treatment of periodontitis.  In a study of 60 patients receiving SRP plus either a 
locally delivered placebo or SIM, there was a greater decrease in gingival 
inflammation and significantly more intrabony defect fill at sites treated with 
scaling and root planing plus SIM (Pradeep & Thorat 2010).  Another similarly 
designed study by the same group examining SIM’s effect in treating molar Class II 
furcation defects in 72 patients resulted in a similar reduction in gingival 
inflammation and greater mean percentage of bone fill in SIM-treated subjects 
(Pradeep et al. 2012).  The authors concluded that locally-delivered SIM provides a 
comfortable and flexible method to improve clinical parameters and also enhance 
bone formation.  Also, 38 subjects with type 2 diabetes similarly treated with SIM 
resulted in the same inflammation reduction with significant intrabony defect fill at 
sites treated with SRP plus locally delivered SIM compared to SRP alone (Pradeep et 
al. 2013).  While the human trials above are supportive of the use of statin treatment 
of periodontitis and other craniofacial defects, Zhang et al. (2014) states that future 
confirmation of these results by other investigators is crucial.   
The differences in weight changes were not significantly different among 
groups from the start to the conclusion of the study.  Further, the mean changes in 
weight for all groups were within 10 grams of the starting weights, or a maximum 
3.3% change in weight from baseline.  Thus, neither the ligature nor a combination 
of ligature with mPEG or any dose of SIM/SIM-mPEG had an effect on weight 
changes in the rats throughout the duration of the study.  In the study mentioned 
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above, Price et al. (2013) also demonstrated no significant weight change in rats 
over the course of study using a SIM/alendronate-β-cyclodextrin complex. 
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CHAPTER 6:  CONCLUSIONS 
 
 SIM/SIM-mPEG, especially 1.5 mg SIM/SIM-mPEG, significantly decreased 
the amount of bone loss and inflamed tissue in experimental periodontitis near the 
injection site.  However, the mPEG carrier appears to increase inflammation and 
may not be well-suited for conjugation with SIM.   
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CHAPTER 7:  FUTURE DIRECTIONS 
 
Currently, researchers at the University of Nebraska Medical Center College 
of Pharmacy have developed a new SIM pro-drug in which SIM has been conjugated 
with pyrophosphate.  This pro-drug is currently in experimental phases to test its 
bone anabolic and anti-inflammatory potential. 
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Table 1 
 
Experimental groups of the pilot study. 
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Table 2 
 
Experimental groups of the core study. 
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Table 3 
 
The intra-class correlation coefficient (ICC), evaluating the intra-examiner reliability 
between µ-CT measurements collected at two different measurement times. 
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Table 4 
 
Pearson correlation coefficients comparing area of inflammatory infiltrate/total 
area of CT above the alveolar bone crest and bone loss at M1D and M2M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Figure 1 
 
Synthesis of the amphiphilic macromolecular prodrug SIM-mPEG. 
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Figure 2 
 
4-0 silk ligature in place around the maxillary right second molar. 
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Figure 3 
 
Local injections delivered to the palate between M1 and M2. 
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Figure 4 
 
Alignment of specimens on three axes prior to obtaining measurements. 
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Figure 5 
 
Histology shows papillary epithelium (top) and bone (bottom) and teeth M2-M1 at 
100X magnification.  µ-CT specimens reveal orientation of sagittal section used for 
measurements. 
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Figure 6 
 
The effect of ligature-alone, ligature + LPS, and LPS-alone on the alveolar crest 
height at the distal of M1 as measured histologically. 
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Figure 7 
 
The effect of ligature-alone, ligature + LPS, and LPS-alone on the alveolar crest 
height at the distal of M1 as measured using µ-CT. 
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Figure 8 
 
The effect of ligature-alone, ligature + LPS, and LPS-alone on the subepithelial 
inflammatory score. 
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Figure 9 
 
Distribution of differences in weight from start to finish of the study among groups 
(p = 0.1315). 
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Figure 10 
 
CEJ-ABC at primary outcome site as measured by µ-CT. 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 11 
 
CEJ-ABC at M2M as measured by µ-CT. 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 12 
 
CEJ-ABC at M2D as measured by µ-CT. 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 13 
 
The length of CT attachment as measured histologically. 
 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 14 
 
The area of inflammatory infiltrate between M1 and M2. 
 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 15 
 
Lymphocytic infiltrate interproximally between M1 and M2. 
 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 16 
 
PMN infiltrate interproximally between M1 and M2. 
 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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Figure 17 
 
Uninflamed CT fibers interproximally between M1 and M2. 
 
 
Group 1 = ligature-alone  
Group 3 = mPEG  
Group 5 = 0.5 mg SIM/SIM-mPEG  
Group 7 = 1.0 mg SIM/SIM-mPEG  
Group 9 = 1.5 mg SIM/SIM-mPEG  
Groups 2, 4, 6, 8, 10 = contralateral untreated control of preceding treatment 
group 
 
*  p < 0.05 
** p < 0.001 
*** p < 0.0001 
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APPENDIX 
Animal # Area of 
inflammation 
Supracrestal 
CT area 
% INF CEJ - apical extent 
of epithelium 
276L 0 0 0 0 
276R 0.03527 0.1146 0.307766143 0.2586 
277L 0.03101 0.2531 0.28411 0.1972 
277R 0.16299 0.8278 0.196895385 0.3197 
278L 0.02811 0.1275 0.220470588 0.03171 
278R 0.067498 0.253898 0.265846915 0.3648 
279L 0 0 0 0 
279R 0.14042 0.5286 0.2656451 0.1772 
280L 0.03676 0.1651 0.222652938 0.1018 
280R 0.05145 0.18826 0.273292255 0.2042 
281L 0.0118 0.1612 0.073200993 0.05389 
281R 0.04174 0.542 0.07701107 0.192 
282L 0.02962 0.1842 0.160803474 0.24 
282R 0.05657 0.3005 0.188252912 0.3394 
283L 0 0 0 0 
283R 0.1106 0.3239 0.341463415 0.3128 
284L 0.01811 0.1507 0.120172528 0.1811 
284R 0 0 0 0 
285L 0 0 0 0 
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CEJ - bone M1DB CEJ - bone μCT M2MB CEJ - bone μCT M2DB CEJ - bone 
μCT 
0 0 0 0 
0.4937 0 0 0 
0.3646 0.405 0.468 0.51 
0.9866 0.716 0.523 0.684 
0.2489 0.326 0.34 0.308 
0.587 0.8 0.74 0.465 
0 0.456 0.395 0.421 
0.8089 1.079 1.019 1.06 
0.2857 0.356 0.322 0.508 
0.4803 1.03 1.007 0.393 
0.3159 0.288 0.402 0.218 
0.6752 1.095 1.129 0.857 
0.4265 0.465 0.436 0.626 
0.5711 1.396 0.652 0.919 
0 0.469 0.556 0.349 
0.5928 0.93 0.78 0.776 
0.3761 0.487 0.597 0.668 
0 1.327 1.477 1.22 
0 0.504 0.445 0.218 
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Lymphocyte Plasma 
Cell 
Macrophage PMN CT Blood 
Vessel 
Fibroblast Space 
0 0 0 0 0 0 0 0 
15 0 0 1 59 4 21 0 
6 0 0 3 68 5 18 0 
11 3 0 7 46 6 22 5 
2 0 0 3 70 4 19 1 
10 0 0 7 59 4 220 0 
0 0 0 0 0 0 0 0 
7 1 0 3 55 10 24 0 
8 0 0 1 67 6 15 3 
10 0 0 3 61 6 14 6 
5 0 0 0 63 7 25 0 
9 0 0 4 59 6 22 0 
5 0 0 2 72 6 15 0 
16 0 0 5 58 3 17 0 
0 0 0 0 0 0 0 0 
7 4 0 6 34 17 21 11 
5 0 0 2 67 2 22 2 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
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Animal # Area of 
inflammation 
Supracrestal 
CT area 
% INF CEJ - apical extent of 
epithelium 
285R 0 0 0 0 
286L 0 0 0 0 
286R 0.12256 0.4113 0.297982008 0.2093 
287L 0.012699 0.3019 0.042063597 0.3369 
287R 0.0798 0.2237 0.35672776 0.4961 
288L 0.007466 0.046576 0.160297149 0.1506 
288R 0.1374 0.2608 0.526840491 0.3733 
289L 0.03009 0.2237 0.134510505 0.02844 
289R 0.0508 0.2648 0.1918429 0.3565 
290L 0.0368 0.2383 0.154427193 0.2359 
290R 0.077871 0.2673 0.291324355 0.3726 
291L 0.01841 0.05773 0.31889832 0.3707 
291R 0.04632 0.2249 0.205958204 0.275 
292L 0 0 0 0 
292R 0.117 0.3646 0.320899616 0.09134 
293L 0.02362 0.1466 0.16111869 0.1931 
293R 0.12644 0.2989 0.423017732 0.4749 
294R 0.11446 0.2689 0.425660097 0.3942 
295L 0.03259 0.15 0.217266667 0.04286 
 
65 
 
 
CEJ - bone M1DB CEJ - bone μCT M2MB CEJ - bone μCT M2DB CEJ - bone 
μCT 
0 0.951 1.014 0.61 
0 0.494 0.432 0.204 
0.6464 1.014 0.9 0.404 
0.5137 0.464 0.56 0.305 
0.6361 0.526 0.604 0.697 
0.3005 0.491 0.436 0.334 
0.5591 0.692 0.773 1.15 
0.2993 0.399 0.456 0.265 
0.6727 0.662 0.746 0.726 
0.4833 0.542 0.542 0.247 
0.6211 0.863 0.845 1.118 
0.4912 0.516 0.509 1.034 
0.7518 0.771 0.682 0.668 
0 0.339 0.262 0.363 
0.4393 0.829 0.728 0.61 
0.3841 0.575 0.611 0.377 
1.043 0.887 0.909 1.176 
0.7406 0.937 0.883 0.451 
0.1563 0.351 0.321 0.421 
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Lymphocyte Plasma 
Cell 
Macrophage PMN CT Blood 
Vessel 
Fibroblast Space 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
23 0 0 16 33 16 11 1 
2 0 0 1 75 8 12 0 
10 2 0 6 40 3 27 0 
9 0 0 3 39 0 17 32 
8 0 5 5 53 10 19 0 
11 0 0 2 50 9 25 1 
7 0 0 1 58 6 28 0 
5 0 0 2 67 6 20 0 
0 0 0 0 0 0 0 0 
7 0 0 2 55 2 28 6 
5 0 1 9 49 6 24 6 
0 0 0 0 0 0 0 0 
24 2 2 3 44 2 19 5 
1 0 2 4 50 10 33 0 
8 0 0 3 50 7 29 3 
9 0 0 6 52 11 20 2 
7 0 1 2 57 15 18 0 
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Animal # Area of 
inflammation 
Supracrestal 
CT area 
% INF CEJ - apical extent 
of epithelium 
295R 0.07346 0.26 0.282538462 0.4883 
296L 0.02876 0.09973 0.288378622 0.08493 
296R 0.09621 0.2344 0.410452218 0.4342 
298L 0.01446 0.09679 0.149395599 0.1102 
298R 0.2613 0.2818 0.927253371 0.4233 
299L 0.014849 0.1046 0.141959847 0.2494 
299R 0.1085 0.2192 0.494981752 0.3103 
300L 0.021 0.1279 0.164190774 0.1003 
300R 0.09871 0.1628 0.606326781 0.397 
301L 0.01836 0.08773 0.209278468 0.2126 
301R 0.12928 0.5449 0.237254542 0.2635 
302L 0.07739 0.2496 0.31005609 0.06813 
302R 0.3066 0.06737 4.550987086 0.2872 
303L 0.041422 0.1382 0.299725036 0.08889 
303R 0.08393 0.3003 0.279487179 0.2423 
304L 0.02749 0.1226 0.224225122 0.1571 
304R 0.1389 0.3803 0.36523797 0.2723 
305L 0.06316 0.205 0.308097561 0.2231 
305R 0.1726 0.5196 0.332178599 0.505 
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CEJ - bone M1DB CEJ - bone μCT M2MB CEJ - bone μCT M2DB CEJ - bone 
μCT 
0.7284 0.892 0.928 1.191 
0.3492 0.506 0.611 1.416 
0.7414 1.093 1.297 0.628 
0.283 0.354 0.427 0.262 
0.8627 0.61 0.634 0.421 
0.4948 0.592 0.726 0.392 
0.8558 0.901 0.944 0.552 
0.2959 0.416 0.483 0.538 
0.5529 0.658 0.634 0.653 
0.338 0.454 0.497 0.261 
0.873 0.65 0.731 0.723 
0.345 0.496 0.496 0.497 
0.4352 0.702 0.688 0.552 
0.3942 0.487 0.579 0.438 
0.6772 0.868 0.826 0.818 
0.3818 0.52 0.526 0.384 
0.6412 0.695 0.704 1.278 
0.4365 0.717 0.599 0.569 
0.6878 0.546 0.81 1.408 
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Lymphocyte Plasma 
Cell 
Macrophage PMN CT Blood 
Vessel 
Fibroblast Space 
7 1 0 0 59 11 22 0 
12 2 0 0 57 0 28 0 
15 1 1 1 65 0 14 3 
11 0 0 2 54 3 30 0 
27 0 1 13 38 12 8 1 
17 0 0 8 52 0 21 4 
12 0 0 2 37 13 29 7 
7 0 0 6 60 6 17 5 
21 1 0 7 37 10 23 1 
3 0 0 1 63 5 27 0 
7 0 0 1 69 7 16 0 
5 0 0 2 64 10 17 2 
7 1 0 2 60 1 19 0 
10 1 0 0 60 2 27 0 
11 0 0 2 68 5 12 2 
11 0 0 0 61 3 16 9 
5 1 0 4 62 6 21 0 
6 0 0 1 74 5 14 0 
10 1 0 5 58 5 19 2 
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Animal # Area of 
inflammation 
Supracrestal 
CT area 
% INF CEJ - apical extent 
of epithelium 
306L 0.0431 0.1841 0.234111896 0.07888 
306R 0.2223 0.6022 0.369146463 0.1489 
307L 0.02951 0.1032 0.285949612 0.1843 
307R 0 0 0 0 
308L 0 0 0 0 
308R 0.1129 0.3755 0.300665779 0.4524 
309L 0.04346 0.203 0.21408867 0.1579 
309R 0.05539 0.2403 0.230503537 0.8195 
310L 0.02961 0.1432 0.206773743 0.1021 
310R 0.1432 0.5387 0.265825135 0.2229 
311L 0.06287 0.1427 0.440574632 0.2041 
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CEJ - bone M1DB CEJ - bone μCT M2MB CEJ - bone μCT M2DB CEJ - bone 
μCT 
0.3283 0.344 0.37 0.262 
0.7032 0.735 0.657 0.844 
0.3417 0.475 0.481 0.23 
0 0 0 0 
0 0 0 0 
0.8342 0.851 0.744 1.203 
0.4861 0.753 0.89 0.741 
0.8816 1.032 0.859 1.139 
0.2272 0.403 0.325 0.218 
0.7432 0.649 1.13 0.399 
0.4173 0.542 0.455 0.524 
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Lymphocyte Plasma 
Cell 
Macrophage PMN CT Blood 
Vessel 
Fibroblast Space 
3 0 0 1 71 5 18 1 
10 1 0 4 63 7 15 0 
6 0 0 0 64 8 22 0 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
9 3 0 6 57 2 22 1 
8 0 0 2 70 8 10 2 
6 0 0 2 62 3 25 3 
5 0 0 0 72 5 18 0 
5 0 0 1 71 3 20 0 
7 0 0 1 63 8 21 0 
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Animal # Area of 
inflammation 
Supracrestal 
CT area 
% INF CEJ - apical extent 
of epithelium 
311R 0.07683 0.2554 0.30082224 0.3163 
312L 0.03843 0.1483 0.259136885 0.1664 
312R 0.1102 0.2439 0.451824518 0.3204 
313L 0.04793 0.1588 0.301826196 0.1464 
313R 0.06563 0.4037 0.162571216 0.2082 
314L 0.05452 0.1602 0.340324594 0.1735 
314R 0.164 0.3915 0.41890166 0.23 
315L 0 0 0 0 
315R 0.0633 0.2273 0.278486582 0.224 
316L 0 0 0 0 
316R 0.05354 0.2452 0.218352365 0.1441 
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CEJ - bone M1DB CEJ - bone μCT M2MB CEJ - bone μCT M2DB CEJ - bone 
μCT 
0.4034 0.508 0.546 1.277 
0.3171 0.423 0.437 0.416 
0.456 0.451 0.52 0.668 
0.4123 0.481 0.643 0.962 
0.6358 0.959 0.734 1.118 
0.4716 0.507 0.445 0.6 
0.7567 0.69 0.771 0.704 
0 0.377 0.345 0.422 
0.4981 0.501 0.542 0.581 
0 0 0 0 
0.4403 0.753 0.793 0.613 
 
 
 
 
 
 
 
 
 
75 
 
 
Lymphocyte Plasma 
Cell 
Macrophage PMN CT Blood 
Vessel 
Fibroblast Space 
9 3 0 2 68 2 15 0 
4 0 0 0 69 10 16 0 
21 1 0 2 54 6 15 1 
15 1 0 0 54 5 24 1 
8 1 0 2 62 7 18 2 
13 0 1 1 63 2 20 1 
17 1 0 6 49 5 16 6 
0 0 0 0 0 0 0 0 
5 0 0 1 64 7 23 0 
0 0 0 0 0 0 0 0 
12 1 1 0 60 3 24 0 
 
KEY: 
276-283 = Ligature-alone 
284-287 & 292-295 = mPEG 
288-291 & 296-300 = 0.5 mg SIM/SIM-mPEG 
301-308 = 1.0 mg SIM/SIM-mPEG 
309-316 = 1.5 mg SIM/SIM-mPEG 
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Animal # Starting Weight Finishing Weight Difference 
276 304 318 -14 
277 296 289 7 
278 304 297 7 
279 324 310 14 
280 309 314 -5 
281 323 331 -8 
282 315 310 5 
283 326 348 -22 
284 328 324 4 
285 299 309 -10 
286 300 295 5 
287 314 317 -3 
288 292 294 -2 
289 283 277 6 
290 270 278 -8 
291 300 309 -9 
292 273 279 -6 
293 297 295 2 
294 330 315 15 
295 326 313 13 
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Animal # Starting Weight Finishing Weight Difference 
296 310 315 -5 
298 302 301 1 
299 288 292 -4 
300 324 312 12 
301 348 340 8 
302 325 317 8 
303 401 394 7 
304 303 298 5 
305 353 342 11 
306 353 335 18 
307 334 346 -12 
308 352 352 0 
309 324 320 4 
310 340 326 14 
311 337 327 10 
312 309 300 9 
313 342 334 8 
314 336 322 14 
315 340 349 -9 
316 328 308 20 
 
